Combination Therapy
Approved for: NSCLC
Atezolizumab (Tecentriq) is a FDA-approved treatment for non-small cell lung cancer (NSCLC).
It is used: With bevacizumab, paclitaxel, and carboplatin or paclitaxel albumin-stabilized nanoparticle formulation and carboplatin as first-line therapy in adults with non-squamous non-small cell lung cancer that does not have a mutation in the EGFR gene or ALK gene.
